{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Katie", "organization": "", "rank": 1, "lastname": "THOMAS"}], "original": "By KATIE THOMAS"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbWide.jpg", "legacy": {"wide": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/12/31/business/31DRUG1/31DRUG1-articleLarge.jpg", "legacy": {"xlarge": "images/2016/12/31/business/31DRUG1/31DRUG1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "398"}, "width": 600, "subtype": "xlarge", "height": 398}, {"type": "image", "url": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "Hefty Price Set on a New Drug That Can Stunt  Muscle Disease", "main": "Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval"}, "print_page": "1", "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Biogen Idec Inc", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Spinal Muscular Atrophy", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Health Insurance and Managed Care", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Food and Drug Administration", "is_major": "N", "rank": "6", "name": "organizations"}], "snippet": "Spinraza, a \u201clife-changing\u201d drug for spinal muscular atrophy, will cost as much as $750,000 for the first year of treatment and $375,000 annually after that....", "source": "The New York Times", "lead_paragraph": "Spinraza, a \u201clife-changing\u201d drug for spinal muscular atrophy, will cost as much as $750,000 for the first year of treatment and $375,000 annually after that.", "word_count": "1098", "pub_date": "2016-12-31T00:40:18+0000", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/12/30/business/spinraza-price.html", "_id": "5866fe7a95d0e039260786c9"}